About Rock Creek Pharmaceuticals (OTCMKTS:RCPIQ)
Rock Creek Pharmaceuticals, Inc. is a pharmaceutical development company. The Company is focused on the discovery, development and commercialization of therapies for chronic inflammatory disease and neurologic disorders. The Company's activities are focused on its lead compound, anatabine citrate (anatabine). Anatabine is a small molecule, cholinergic agonist, which exhibits anti-inflammatory pharmacological characteristics. The Company focuses on dermatological skin diseases, such as psoriasis, eczema and rare or orphan skin disorders, using its formulations of anatabine. The Company has completed Phase I safety studies of its product candidate in Europe. In pre-clinical testing, anatabine demonstrates anti-inflammatory activity in a range of in vitro and in vivo assays.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value($0.95) per share
Price / Book0.00
Return on EquityN/A
Return on AssetsN/A
Rock Creek Pharmaceuticals (OTCMKTS:RCPIQ) Frequently Asked Questions
What is Rock Creek Pharmaceuticals' stock symbol?
Rock Creek Pharmaceuticals trades on the OTCMKTS under the ticker symbol "RCPIQ."
How were Rock Creek Pharmaceuticals' earnings last quarter?
Rock Creek Pharmaceuticals Inc (OTCMKTS:RCPIQ) released its quarterly earnings data on Monday, November, 11th. The company reported ($0.02) earnings per share for the quarter. The business had revenue of $2.26 million for the quarter, compared to analysts' expectations of $1.70 million. View Rock Creek Pharmaceuticals' Earnings History.
Who are some of Rock Creek Pharmaceuticals' key competitors?
Some companies that are related to Rock Creek Pharmaceuticals include BG Medicine (BGMD), China Gerui Advanced Materials Group (CHOPF), Seal123 (WTSLQ), Glori Energy (GLRI), Prospect Global Resources (PGRX), QF Liquidation (QTWWQ), M Pharmaceutical (MPHMF), Azure Midstream Pa Com Unit Ltd Partner Int (AZURQ), Roust (CEDCQ), James River Coal (JRCCQ), Violin Memory (VMEMQ), Noranda Aluminum (NORNQ), DS Healthcare Group (DSKX), Paragon Shipping (PRGNF), Erickson (EACIQ), Trimedyne (TMED), Ignite Restaurant Group (IRGTQ) and Imris (IMRSQ).
Who are Rock Creek Pharmaceuticals' key executives?
Rock Creek Pharmaceuticals' management team includes the folowing people:
- Michael John Mullan Ph.D. M.D., Chairman of the Board, Office of President, Chief Executive Officer (Age 59)
- William L. McMahon, Chief Financial Officer (Age 64)
- Theodore Jenkins, Secretary, Vice President - Corporate Strategy & Development
- Lee M. Canaan, Independent Director (Age 59)
- Robert W. Scannell, Independent Director (Age 57)
How do I buy Rock Creek Pharmaceuticals stock?
Shares of Rock Creek Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Rock Creek Pharmaceuticals' stock price today?
One share of Rock Creek Pharmaceuticals stock can currently be purchased for approximately $0.00.
How big of a company is Rock Creek Pharmaceuticals?
Rock Creek Pharmaceuticals has a market capitalization of $200,000.00.
How can I contact Rock Creek Pharmaceuticals?
Rock Creek Pharmaceuticals' mailing address is 2040 WHITFIELD AVE. SUITE 300, SARASOTA FL, 34243. The company can be reached via phone at 844-727-0727 or via email at [email protected]
MarketBeat Community Rating for Rock Creek Pharmaceuticals (RCPIQ)MarketBeat's community ratings are surveys of what our community members think about Rock Creek Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Rock Creek Pharmaceuticals (OTCMKTS:RCPIQ) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Rock Creek Pharmaceuticals (OTCMKTS:RCPIQ) Earnings History and Estimates Chart
Rock Creek Pharmaceuticals (OTCMKTS RCPIQ) Earnings History by Quarter
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/11/2013||Q3||($0.02)||$1.70 million||$2.26 million||View||N/A|
Rock Creek Pharmaceuticals (OTCMKTS:RCPIQ) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Rock Creek Pharmaceuticals (OTCMKTS:RCPIQ)
No dividend announcements for this company have been tracked by MarketBeat.com
Rock Creek Pharmaceuticals (OTCMKTS RCPIQ) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.89%
Rock Creek Pharmaceuticals (OTCMKTS RCPIQ) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|3/30/2016||Robert Scannell||Director||Buy||285,714||$0.35||$99,999.90|| |
Rock Creek Pharmaceuticals (OTCMKTS RCPIQ) News Headlines
No headlines for this company have been tracked by MarketBeat.com
Rock Creek Pharmaceuticals (OTCMKTS:RCPIQ) SEC Filings
Financials are not available for this stock.
Rock Creek Pharmaceuticals (OTCMKTS RCPIQ) Stock Chart for Tuesday, December, 12, 2017